Grants for For profit organizations other than small businesses - Federal

The Federal Transit Administration (FTA) announces the opportunity to apply for a total of $1,936,000 in Fiscal Year (FY) 2023 Public Transportation Innovation funds in competitive cooperative agreement awards for projects that enhance mobility innovations for transit. Funds will be awarded for projects that advance emerging technologies, strategies, and innovations in traveler-centered mobility in two distinct areas. Of the total available funds, $968,000 is available for projects to accelerate innovations that improve mobility and enhance the rider experience with a focus on innovative service delivery models, creative financing, novel partnerships, and integrated payment solutions. Another $968,000 is available for projects to develop software solutions that facilitate the provision of integrated demand-response public transportation service that dispatches public transportation fleet vehicles through riders mobile devices or other means.

This announcement is designed to accompany PRMs General NGO Guidelines, which contain additional information on PRMs priorities and NGO funding strategy with which selected organizations must comply, unless otherwise specified in this notice of funding opportunity. Please use both the General NGO Guidelines and this announcement to ensure that your submission is in full compliance with PRM requirements and that the proposed activities are in line with PRMs priorities. Submissions that do not reflect the requirements outlined in these guidelines will not be considered. Where there is differing guidance, instructions in this NOFO announcement supersede any divergent guidance in the NGO Guidelines. The Bureau of Population, Refugees, and Migration is seeking proposals from organizations from North, Central and South America as well as the Caribbean to create a technical secretariat to support the implementation of the Los Angeles Declaration on Migration and Protection, a hemispheric international forum that promotes safe, orderly, and humane migration and access to protection in the Western Hemisphere. Implementation includes supporting meetings of the Declaration and working groups (known as Action Package Committees), tracking work completed on governments commitments, advancing work with key stakeholders, and other work as defined below.

The "DoD Rare Cancers, Idea Development Award" is a grant aimed at supporting early-stage research ideas with high potential impact, which could lead to significant advancements in the diagnosis, treatment, and improved health outcomes for individuals suffering from rare cancers, with a particular focus on innovative research involving nuclear medicine, women's health, and adherence to rigorous study design standards.

This funding opportunity supports innovative research aimed at preventing Alzheimer’s disease and related dementias, particularly in relation to military service and traumatic brain injury, targeting independent researchers from various eligible organizations.

This initiative seeks input from various stakeholders, including businesses, researchers, and government entities, to enhance the recycling and reuse of products and materials, ultimately promoting environmental sustainability and economic resilience.

The U.S. National Science Foundations Directorate for Technology, Innovation and Partnerships (TIP) is charged with accelerating use-inspiredand translationalresearch and development (R) to advance U.S. competitiveness in key technology focus areas. The Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (CFIRE) initiative will accelerate the adoption of cell-free systems, enable new applications of this technology and contribute to the growth of the U.S. bioeconomy. A nascent industry has formed around the ability to carry out biochemical processes, such as DNA transcription/translation, in cell-free in-vitro systems instead of in traditional cell-based in-vivo bio-reactors. This approach has a number of potential advantages, including rapid turn-around, distributed and highly retargetable manufacturing, high-fidelity instrumentation and control of the manufacturing environments without the constraints of biological growth and the interference caused by cell biomass and cell membranes during product purification. Furthermore, cell-free systems can produce products that are challenging to manufacture in cell-based cultures, such as those inherently toxic to cells or hydrocarbon products that are consumed by the cellular machinery. Despite these advantages, present-day cell-free manufacturing is significantly more expensive than cell-based methods and cell-free systems have a limited range of applications. CFIRE aims to: 1. Reduce the cost of cell-free systems; 2. Increase the range and capabilities of cell-free systems; and 3. Develop and demonstrate cost-effective use-inspired applications. CFIRE will address the key limitations of cell-free technology by identifying technical approaches that can enable ongoing cycles of improvement. The objective is to place cell-free technology on an exponential growth path in which reduced costs lead to increasing adoption which, in turn, generates the learning and investment required to further reduce costs. In order to keep the work focused and to stimulate increasing adoption, efforts funded through this initiative will focus on one or more specific use cases. CFIRE seeks significant breakthroughs that will accelerate the adoption of cell-free systems by: (a) Demonstrating the feasibility and advantages of cell-free systems through use-inspired applications with specific emphasis on applications beyond human therapeutics; (b) Creating infrastructure components, such as tools, protocols, kits, datasets, and characterization services that can readily be accessed by third parties; and (c) Investing in workforce components focused on the training of translational talent with the skills and passion to engage in use-driven cell-free applications. CFIRE will use the Ideas Lab process (see PAPPG Chapter II.F.6), starting with an intensive meeting that brings together multiple diverse perspectives. The primary objectives of this Ideas Lab workshop will be to: identify specific opportunities to significantly reduce the cost of cell-free systems; establish acceptable standards for the fidelity and reproducibility; expand the range of capabilities in order to facilitate broader adoption of the technology; and identify and prioritize use-driven applications beyond human therapeutics.

This funding opportunity supports independent researchers in studying the prevention, diagnosis, and treatment of diseases related to military toxic exposures, benefiting Service Members, Veterans, and their families.

The Equitable and Affordable Solutions to Electrification (EAS-E) Home Electrification Prize offers up to $2.4 million in prizes for innovative solutions that advance the electrification retrofits of residential homes across all building types and geographies. The goal is to make electrification more affordable and accessible in existing U.S. homes, with a focus on equitable solutions for all homeowners, including those in low-income and under-resourced communities. The prize supports design solutions, tools, and technology innovations that enable the switch to electric products and reduce carbon emissions. Low-power electrification solutions are strongly encouraged. The competition consists of two phases: Phase 1 focuses on presenting proposed solutions and up to five winners receive a $5,000 cash prize and a $75,000 voucher to work with DOE national laboratories. Phase 2 involves finalizing teams, demonstrating functional prototype solutions, and up to three winners receive prizes, with a top prize of $1 million. The competition is open to individuals, private entities, nonfederal government entities, and academic institutions. For more information, refer to the official rules document.

This funding opportunity provides financial support to organizations that create and manage equine therapy programs aimed at improving the well-being and quality of life for disabled veterans and members of the Armed Forces.

The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative. It aims to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research laboratory, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in the early Fall of 2024, with an expected application due date in November 2024. The NOFO will utilize the U01 mechanism for Research Project Cooperative Agreement (Clinical Trial Not Allowed). Potential applicants are encouraged to view the presentation of this initiative to the NCI Board of Scientific Advisors (BSA), available at: (https://videocast.nih.gov/watch=54423) beginning at 1 hour, 32 minutes, 52 seconds. Presentation slides are downloadable at https://deainfo.nci.nih.gov/advisory/bsa/0324/Maas.pdf.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for a new project, Dignity in Documentation Initiative (DIDI). This effort focuses on global, integrated, and holistic CRSV documentation programming seeking truth and justice for victims and survivors as well as accountability for crimes committed in violation of international human rights and humanitarian law. The DIDI must take a survivor-centered and trauma-informed approach, prioritizing the individual needs and efforts of CRSV survivors, while supporting survivor networks, civil society, and community-based organizations. This solicitation will result in the first tranche of these program efforts, with incremental funding envisioned over the life of the 5-year project, depending on the availability of funding.

The key aspects of this award are: Impact: The SRA is intended to support research designed to have a major impact on the health and well-being of melanoma survivors, their families, and/or caregivers. Impactful research will accelerate the movement of promising ideas into clinical applications or other real-world applications and advance the field of melanoma-specific quality of life and survivorship. Study Design: Applications should clearly articulate and justify the chosen study design. Studies proposing retrospective analyses or prospective enrollment should clearly describe the architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses) and the study population(s). The study population(s) should be representative of the people who are anticipated to benefit from the research. If applicable, questionnaires should be described in sufficient detail to justify interpretation of potential results. Melanoma Consumer Collaboration: For the purposes of the SRA, a melanoma consumer is defined as a melanoma survivor, family member, and/or caregiver who can provide lived experience expertise to the research project team. Applicants to the SRA are required to establish a collaborative research approach with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended melanoma community(ies). The research team must include at least one melanoma consumer or a melanoma-community supporting organization who will be integral to the planning, execution, and implementation of the proposed research. The role of the melanoma consumer collaborator(s) should include providing objective input on the research question being addressed; the study design, execution, and evaluation; and the potential impact of the research outcomes on the health and well-being of melanoma survivors, their families, and/or their caregivers. The melanoma consumer collaborator(s) should be active participants and integrated into the research team; their participation should not be limited only to passive activities (e.g., attending seminars or quarterly team meetings). Additional information and resources for establishing a collaborative research approach with the melanoma consumer community is provided below.Other Important Considerations:Collaborative Research Approaches: Collaborative research approaches create partnerships between scientific researchers and, for the purposes of the SRA, melanoma consumers to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and melanoma consumers collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of the melanoma consumers within the research team. Research results are jointly interpreted, disseminated, and fed back to affected communities and in some instances may be translated into interventions or policy.Collaborative relationships with the melanoma consumer community may be established through integrating melanoma consumers and/or melanoma-community supporting organizations into research teams as co-researchers, advisors, and/or consultants. Examples for implementing collaborative research approaches are listed below, but each research team may pursue other options as appropriate for the proposed research: The research team includes at least one melanoma consumer who will provide advice and consultation throughout the planning and implementation of the research project. The consumer(s) should be able to speak to the needs of the melanoma consumer community, not just speak to their own personal experiences. The research team establishes partnerships with at least one community-supporting organization that provides advice and consultation throughout the planning and implementation of the research project. Community-supporting organizations may include advocacy groups or other formal organizational stakeholders that can speak to the needs of the melanoma consumer community. The research team assembles a melanoma consumer community advisory board. The advisory board may include melanoma consumers, a coalition of community-supporting organizations, or any combination thereof that provides advice and consultation throughout the planning and implementation of the overall program and/or individual research projects.

This funding opportunity supports the development of advanced bioelectronic bandages that can monitor and treat wounds in real-time, specifically targeting military medical care for combat personnel.

This funding opportunity provides up to $1.3 billion to support the development and demonstration of advanced carbon capture technologies for power generation and industrial sectors, targeting a wide range of eligible applicants including educational institutions, nonprofits, and businesses.

This award is to support community development and resilience with geospatial data and digital technology by engaging university-aged youth. The activities anticipated as part of this award will add valuable, free and openly accessible data to digital ecosystems of lower and middle income countries, which in turn can be used by USAID programs and humanitarian assistance activities. The award will specifically focus on youth training, geospatial data collection, and analysis to help communities address local development challenges. Activities will also engage marginalized populations to ensure representation of the diversity of partner country populations. USAID anticipates awarding one to three grants and/or cooperative agreements under this Addendum. Issuance of this Addendum does not constitute an award or commitment on the part of the U.S. Government to make an award, nor does it commit the U.S. Government to pay for costs incurred in the preparation and submission of a Concept Note or Application(s). The actual number of assistance awards is subject to the availability of funds, as well as the viability of eventual full Applications received.

This grant seeks innovative proposals from a wide range of organizations, including universities and small businesses, to develop advanced technologies that enhance national defense capabilities.

The "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH)" grant aims to support research that develops new behavioral measures and data infrastructure to improve the diagnosis, prognosis, and treatment of mental disorders.

This notice announces the opportunity to apply for funding under the Delta Region Maternal Care Coordination Program (Delta MCC). The purpose of this program is to improve and increase access to care for pregnant women and new mothers during and after pregnancy. To support this purpose, the objectives for the Delta MCC are to: 1. Use care coordination strategies to enhance and expand access to perinatal services in the Delta Region through a strong, diverse network of entities that represent the spectrum of care during and after pregnancy; 2. Utilize evidence-based, promising practices and/or value-based care model(s) in the planning and delivery of perinatal services; 3. Identify barriers to providing maternal health care in the region and strategies for addressing such barriers; and 4. Develop and implement deliberate and sustainable strategies of care coordination into policies, procedures, staffing, services, and communication systems (including but not limited to billing for appropriate services and partnering private and public payers). Applicants are encouraged to consider innovative strategies to meet the needs of and support pregnant women and new mothers. Some examples of activities that can be provided include: Provide outreach and education to pregnant women and new mothers on healthy nutrition to reduce risk of hypertension Provide screening and referral of mental health issues such as depression and anxiety including HRSAs Maternal Mental Health Hotline (1-833-TLC-MAMA) Refer pregnant women and new mothers to online or local support groups Recruitment of doula and midwifery services, community health workers, and/or maternal fetal specialist services Support patient care through telehealth Support travel costs, as necessary, of maternal health specialist to travel to pregnant woman Provide education and social support for pregnant women through the development of centering pregnancy (group prenatal care) visits; Provide resources and education to support in-home hypertension management and blood pressure self-monitoring and reporting; Support mobile prenatal and postpartum care visits for pregnant women and new mothers; Utilize development dyad models (mother and infant) to support combined postpartum and infant checkup visits; Support childcare for pregnant women and new mothers during prenatal and postpartum care visits; Applicants are encouraged to consider innovative strategies. Applicants are encouraged to propose ways to achieve these goals through the establishment or continuation of collaborative networks/consortiums of providers and services who support pregnant women and new mothers through pregnancy and post-partum. The networks will focus on reducing risk factors for pregnant women during and after pregnancy through screening and referral to needed services and interventions. HRSA recommends your members consist of a broad array of organizations from both traditional and non-traditional health care entities. Network members may include cross-sector entities such as health care providers, key services for supporting infant and child health, quality program providers, and insurers. See Appendix B for examples of the types of network members. This program funding should be used to complement the work of other organizations and should not duplicate or supplant activities that are funded through other federal mechanisms. The Delta MCC is a four-year program with year one (September 30, 2024 September 29, 2025) a planning year and years two, three, and four (September 30, 2025 September 29, 2028) focused on program implementation. For more details, see Program Requirements and Expectations.

This grant provides funding to early-career researchers focused on melanoma to support their independent research and professional development while fostering collaboration within a network of experts.

This grant provides funding for research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS), specifically targeting projects that have already shown promise in preclinical studies and emphasize the use of biomarkers for therapeutic development.